Neurocognitive Impact of Different Irradiation Modalities for Patients With Grade I-II Skull Base Meningioma:

Who can take part

• Benign meningioma (grade I), or atypical meningioma (grade II)
• Histologic proven of benign meningioma, atypical meningioma or unequivocal radiological diagnosis of skull base meningioma if biopsy is recused
• Indication of irradiation validated by a multidisciplinary meeting
• Age >20 years and <65 years
• Expected overall survival >10 years
• Adjuvant or exclusive irradiation is allowed
• Signed informed consent form
• WHO Performance status equal to 0 or 1
• Patient affiliated to the French social health insurance
• Patient whose neuropsychological abilities allow to follow the requirements of the protocol
• Subject without any history of neurological disease (cerebral stroke, epilepsy, Intra cranial Neurosurgery procedure, meningioma, pituitary adenoma, Parkinson disease,Dementia…) or absence of personality disorders and progressive psychiatric pathology
• Age >20 years and <65 years
• Signed informed consent form
• WHO Performance status equal to 0 or 1
• Subject affiliated to the French social health insurance
• Subject whose neuropsychological abilities allow to follow the requirements of the protocol
• No major cognitive disorder that may compromise the realization of cognitive evaluations, defined as a MoCA score in accordance with the threshold depending on age and educational level according to the GRECOGVASC normative data; Non-inclusion criteria
• Cerebrovascular pathology, presence of other tumors of the nervous system, congenital malformations of the nervous system, multiple sclerosis, Parkinson's disease, organic psychosis (other than dementia), or schizophrenia
• History of epilepsy with antiepileptic drug
• Subject with a history of brain irradiation
• Subject with a history of cancer in the last five years (Excluding skin baso-cellular carcinoma)
• Pregnant/breastfeeding woman
• Any geographical conditions, social and associated psychopathology that may compromise the subject's ability to participate in the study
• Participation in a therapeutic trial - Subject deprived of freedom or under guardianship

Who cannot take part

• Participation in a therapeutic trial evaluating a radiotherapy schedule or a new drug or combination for less than 30 days
• Cerebrovascular pathology, presence of other tumors of the nervous system, congenital malformations of the nervous system, multiple sclerosis, Parkinson's disease, organic psychosis (other than dementia), or schizophrenia
• Uncontrolled epilepsy
• Patient with a history of brain irradiation
• Patient with a history of cancer in the last five years (excluding skin baso-cellular carcinoma)
• Any geographical conditions, social and associated psychopathology that may compromise the patient's ability to participate in the study
• Hypersensibility to Gadolinium; Participants free of brain disease or cancer history:
• Patient with mutation in a known predisposition gene (NF-2, SMARCE-1)
• Other localization than skull base meningioma
• Histology/radiological features rather different than grade I-II meningioma
• Histologic proven grade III meningioma
• Contraindication to MRI
• Pregnant/breastfeeding woman
• Patient deprived of freedom or under guardianship

Other criteria

• Patients: